title: Mouse Models for Assessing the Protective Efficacy of Lactobacillus gasseri SBT2055 against Helicobacter suis Infection Associated with the Development of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.
abstract: BACKGROUND
  Helicobacter suis strain TKY infection has been strongly associated with the development of gastric mucosa-associated lymphoid tissue (MALT) lymphoma in a C57BL/6J mouse model.
  
  
  METHODS
  1. C57BL/6J mice were intragastrically administered Lactobacillus strains once daily with 10(8)-10(9) colony-forming units (CFU), starting 2 days before intragastric infection with H. suis TKY (approximately 1 × 10(4) copies of 16S rRNA genes) or H. pylori Sydney strain 1 (SS1; 3 × 10(8) CFU) and continuing for 14 days after infection. 2. C57BL/6J mice were given powdered feed mixed with lyophilized L. gasseri SBT2055 (LG2055) cells (5 × 10(8) CFU/g), starting 2 weeks before intragastric infection with H. suis TKY and continuing 12 months after infection.
  
  
  RESULTS
  1. Among the 5 Lactobacillus strains that we examined, only LG2055 exhibited significantly preventive efficacy against both H. suis TKY and H. pylori SS1 at day 15 after infection. 2. Dietary supplementation with LG2055 protected mice from the formation of round protrusive lesions in the gastric fundus 12 months after infection with H. suis TKY, whereas such lesions had developed in the gastric fundus of nonsupplemented mice 12 months after infection. In addition, the formation of lymphoid follicles in gastric mucus layers was suppressed by dietary LG2055 at 3 months after infection.
  
  
  CONCLUSIONS
  LG2055 administration is effective for suppressing the progression of gastric MALT lymphoma by reducing H. suis colonization.
authors: Department of Infection Control and Immunology, Kitasato Institute for Life, Sciences and Graduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
authors: Hidenori
authors: H
authors: Matsui
authors: Center for Clinical Pharmacy and Clinical Sciences, School of Pharmaceutical Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
authors: Tetsufumi
authors: T
authors: Takahashi
authors: Center for Clinical Pharmacy and Clinical Sciences, School of Pharmaceutical Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
authors: Anders
authors: A
authors: Øverby
authors: Laboratory of Molecular Cell Biology, School of Pharmacy, Nihon University, Funabashi-shi, Chiba, Japan.
authors: Somay Yamagata
authors: SY
authors: Murayama
authors: Department of Infection Control and Immunology, Kitasato Institute for Life, Sciences and Graduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
authors: Haruno
authors: H
authors: Yoshida
authors: Department of Animal Science, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, Japan.
authors: Yuji
authors: Y
authors: Yamamoto
authors: Department of Animal Science, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, Japan.
authors: Keita
authors: K
authors: Nishiyama
authors: Milk Science Research Institute, Megmilk Snow Brand Co., Ltd., Kawagoe, Saitama, Japan.
authors: Yasuyuki
authors: Y
authors: Seto
authors: Department of Infection Control and Immunology, Kitasato Institute for Life, Sciences and Graduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
authors: Takashi
authors: T
authors: Takahashi
authors: Department of Animal Science, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, Japan.
authors: Takao
authors: T
authors: Mukai
authors: Center for Clinical Pharmacy and Clinical Sciences, School of Pharmaceutical Sciences, Kitasato University, Minato-ku, Tokyo, Japan.
authors: Masahiko
authors: M
authors: Nakamura
mesh_terms: D000818:Animals; D019587:Dietary Supplements / Q000382:microbiology; D004195:Disease Models, Animal; D005753:Gastric Mucosa / Q000382:microbiology / Q000473:pathology; D016481:Helicobacter Infections / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control*; D018247:Helicobacter heilmannii / Q000472:pathogenicity*; D016480:Helicobacter pylori / Q000472:pathogenicity; D007778:Lactobacillus / Q000378:metabolism*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000382:microbiology / Q000517:prevention & control* / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D019936:Probiotics / Q000627:therapeutic use*
keywords: C57BL/6 mouse; Helicobacter suis; Lactobacillus gasseri; MALT lymphoma; quantitative PCR